Ken Yood

Nov 29, 2024 | mondaq.com | Nili S. Yolin |Ken Yood |Brian Platton

Another day, another legal challenge to New York's overhaul of the Consumer Directed Personal Assistance Program (CDPAP). In an emergency petition filed Nov.

Nov 27, 2024 | mondaq.com | Ken Yood |Benjamin A. Steinberg

Pursuant to new regulations issued by the U.S. Drug Enforcement Administration (DEA) and U.S. Department of Health and Human Services (HHS) (collectively, the Agencies) on Nov. 11, 2024, providers will be able to continue prescribing Schedule II-V controlled medications via telemedicine without an in-person evaluation until Dec. 31, 2025. This is the third extension of the telemedicine flexibilities and is intended to maintain the status quo while the Agencies develop a longer-term solution.

Nov 26, 2024 | jdsupra.com | Ken Yood

Pursuant to new regulations issued by the U.S. Drug Enforcement Administration (DEA) and U.S. Department of Health and Human Services (HHS) (collectively, the Agencies) on Nov. 11, 2024, providers will be able to continue prescribing Schedule II-V controlled medications via telemedicine without an in-person evaluation until Dec. 31, 2025. This is the third extension of the telemedicine flexibilities and is intended to maintain the status quo while the Agencies develop a longer-term solution.

Nov 13, 2024 | mondaq.com | Ken Yood |Shalyn Watkins |John Saran |Sam Jacobs

Holland & Knight recently hosted a virtual roundtable discussion with Sheila Tatayon, assistant deputy director of Health Systems Compliance and chief counsel for California's Office of Health Care Affordability (OHCA), and Holland & Knight Healthcare Partners Kenneth Yood and John Saran. Holland & Knight Associate Shalyn Watkins moderated the presentation.

Oct 3, 2024 | mondaq.com | Tom Stephenson |John Saran |Ken Yood |Morgan Ivey

California Gov. Gavin Newsom vetoed Assembly Bill (AB) 3129 on Sept. 28, 2024, citing the State's Office of Health Care Affordability's (OHCA) role in studying healthcare consolidation and transactions. Newsom's veto may signal potential challenges for states seeking to reconsider their regulatory frameworks in 2025.